Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2016

01-09-2016 | Original Article

Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates

Authors: J. Ward, C. Wood, K. Rouch, D. Pienkowski, H. H. Malluche

Published in: Osteoporosis International | Issue 9/2016

Login to get access

Abstract

Summary

Apparent modulus and failure stress of trabecular bone structure from 45 women with osteoporosis treated with bisphosphonates for varying durations were studied using finite element analyses and statistical modeling. Following adjustments for patient age and bone volume, increasing bisphosphonate treatment duration for up to 7.3 years was associated with treatment–time-dependent increases in bone apparent modulus and failure stress. Treatment durations exceeding 7.3 years were associated with time-dependent decreases in apparent modulus and failure stress from the peak values observed.

Introduction

The purpose of this study was to clarify the relationship between bisphosphonate (BP) treatment duration and human bone quality. This study quantified changes in the apparent modulus and failure stress of trabecular bone biopsied from patients with osteoporosis who were treated with BPs for widely varying durations.

Methods

Forty-five iliac crest bone samples were obtained from women with osteoporosis who were continuously treated with oral BPs for varying periods of up to 16 years. Micro-CT imaging was used to develop three-dimensional virtual models of the trabecular bone from these samples. Apparent modulus and failure stress of these virtual models were determined using finite element analyses (FEA). Polynomial regression and cubic splines, adjusted for relevant (age and BV/TV) covariates, were used to statistically model the data and quantify the relationships between BP treatment duration and apparent modulus or failure stress.

Results

Second-order polynomial models were needed to relate apparent modulus or failure stress to BP treatment duration. These models showed that these bone quality parameters (a) increased with increasing BP treatment duration up to approximately 7.3 years, (b) reached a maximum at this (~7.3 years) time, and then (c) declined with BP treatment durations exceeding ~7.3 years. A similar result was obtained by modeling with cubic splines.

Conclusions

Changes in FEA-derived apparent stiffness and failure stress are attributable to changes in trabecular bone structure, which in turn are related to the duration of BP treatment. These relationships are evident even after adjustments are made in the statistical models for changes in age and BV/TV. According to these models, increases in trabecular bone apparent stiffness and failure stress linked to BPs cease and appear to reverse after approximately 7.3 years of treatment. Conclusions regarding optimal BP therapy duration await study of additional bone quality parameters.
Literature
1.
Schmidt GA, Horner KE, McDanel DL, Ross MB, Moores KG (2010) Risks and benefits of long-term bisphosphonate therapy. Am J Health Syst Pharm 67(12):994–1001CrossRefPubMed
2.
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100(6):1475–1480
3.
4.
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104(10):1363–1374CrossRefPubMedPubMedCentral
5.
Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333(22):1437–1443CrossRefPubMed
6.
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082CrossRefPubMed
7.
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352CrossRefPubMed
8.
Bilezikian JP (2009) Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 122(2 Suppl):S14–S21CrossRefPubMed
9.
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938CrossRefPubMed
10.
Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34(1):195–202CrossRefPubMed
11.
Dell RM, Adams AL, Greene DF et al (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27(12):2544–2550CrossRefPubMed
12.
Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294CrossRefPubMed
13.
Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE (2012) Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172(12):930–936CrossRefPubMed
14.
Whitaker M, Guo J, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366(22):2048–2051CrossRefPubMed
15.
Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35CrossRefPubMedPubMedCentral
16.
Recker RR, Lewiecki EM, Miller PD, Reiffel J (2009) Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122(2 Suppl):S22–S32CrossRefPubMed
17.
Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301CrossRefPubMed
18.
19.
Bala Y, Depalle B, Farlay D et al (2012) Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 27(4):825–834CrossRefPubMed
20.
Nazarian A, Stauber M, Zurakowski D, Snyder BD, Muller R (2006) The interaction of microstructure and volume fraction in predicting failure in cancellous bone. Bone 39(6):1196–1202CrossRefPubMed
21.
Karim L, Vashishth D (2011) Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone. J Orthop Res 29(11):1739–1744CrossRefPubMedPubMedCentral
22.
Turner CH (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13(2):97–104CrossRefPubMed
23.
Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34(4):736–746CrossRefPubMed
24.
25.
Pistoia W, van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P (2002) Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images. Bone 30(6):842–848CrossRefPubMed
26.
Chevalier Y, Pahr D, Allmer H, Charlebois M, Zysset P (2007) Validation of a voxel-based FE method for prediction of the uniaxial apparent modulus of human trabecular bone using macroscopic mechanical tests and nanoindentation. J Biomech 40(15):3333–3340CrossRefPubMed
27.
Macneil JA, Boyd SK (2008) Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone 42(6):1203–1213CrossRefPubMed
28.
Harrison NM, McDonnell P, Mullins L, Wilson N, O’Mahoney D, McHugh PE (2013) Failure modelling of trabecular bone using a non-linear combined damage and fracture voxel finite element approach. Biomech Model Mechanobiol 12(2):225–241CrossRefPubMed
29.
30.
Britton JM, Davie MW (1990) Mechanical properties of bone from iliac crest and relationship to L5 vertebral bone. Bone 11(1):21–28CrossRefPubMed
31.
Mosekilde L, Viidik A, Mosekilde L (1985) Correlation between the compressive strength of iliac and vertebral trabecular bone in normal individuals. Bone 6(5):291–295CrossRefPubMed
32.
Neo M, Herbst H, Voigt CF, Gross UM (1998) Temporal and spatial patterns of osteoblast activation following implantation of beta-TCP particles into bone. J Biomed Mater Res 39(1):71–76CrossRefPubMed
33.
Malluche HH, Monier–Faugere MC (1997) In: Avioli LV, Krane SM (eds) Bone biopsies: a modern approach in metabolic bone disease, 3rd edn. WB Saunders Co, Philadelphia, pp 237–273
34.
Malluche HHMH, Monier-Faugere MC (2008) Bone biopsy in patients with osteoporosis. Curr Osteoporos Rep 5(4):146–152CrossRef
35.
Malluche HH M-FM (1986) Atlas of mineralized bone histology. Karger
36.
Malluche HH, Porter DS, Monier-Faugere MC, Mawad H, Pienkowski D (2012) Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 23(3):525–532CrossRefPubMedPubMedCentral
37.
van Rietbergen B, Weinans H, Huiskes R, Odgaard A (1995) A new method to determine trabecular bone elastic properties and loading using micromechanical finite-element models. J Biomech 28(1):69–81CrossRefPubMed
38.
Waarsing JH, Day JS, Weinans H (2004) An improved segmentation method for in vivo micro-CT imaging. J Bone Miner Res 19(10):1640–1650
39.
Ruegsegger P, Koller B, Muller R (1996) A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58(1):24–29CrossRefPubMed
40.
Ding M, Odgaard A, Hvid I (1999) Accuracy of cancellous bone volume fraction measured by micro-CT scanning. J Biomech 32(3):323–326CrossRefPubMed
41.
Wilkerson LT (2012) Finite element analysis of cancellous bone. Theses and Dissertations: Mechanical Engineering, University of Kentucky
42.
Burkhart TA, Andrews DM, Dunning CE (2013) Finite element modeling mesh quality, energy balance and validation methods: a review with recommendations associated with the modeling of bone tissue. J Biomech 46(9):1477–1488CrossRefPubMed
43.
Polly BJ, Yuya PA, Akhter MP, Recker RR, Turner JA (2012) Intrinsic material properties of trabecular bone by nanoindentation testing of biopsies taken from healthy women before and after menopause. Calcif Tissue Int 90(4):286–293CrossRefPubMed
44.
Bevill G, Keaveny TM (2009) Trabecular bone strength predictions using finite element analysis of micro-scale images at limited spatial resolution. Bone 44(4):579–584CrossRefPubMed
45.
Un K, Bevill G, Keaveny TM (2006) The effects of side-artifacts on the elastic modulus of trabecular bone. J Biomech 39(11):1955–1963CrossRefPubMed
46.
Wood S (2006) Generalized additive models: an introduction with R, 1st edn. Chapman & Hall/CRC, New York
47.
Wahba G (1990) Spline models for observational data, 1st edn. SIAM, PhiladelphiaCrossRef
48.
Ruppert D, Wand M, Carrol RJ (2003) Semiparametric regression, 1st edn. Cambridge University Press, New YorkCrossRef
49.
Borah B, Dufresne TE, Ritman EL et al (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39(2):345–352CrossRefPubMed
50.
Day JS, Ding M, Bednarz P et al (2004) Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 22(3):465–471CrossRefPubMed
51.
Keaveny TM, Hoffmann PF, Singh M et al (2008) Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 23(12):1974–1982CrossRefPubMedPubMedCentral
52.
Imai K, Ohnishi I, Matsumoto T, Yamamoto S, Nakamura K (2009) Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 20(5):801–810CrossRefPubMed
53.
Lewiecki EM, Keaveny TM, Kopperdahl DL et al (2009) Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 94(1):171–180CrossRefPubMed
54.
Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S (2010) A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res 25(12):2558–2571CrossRefPubMedPubMedCentral
55.
56.
Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17(7):1139–1147CrossRefPubMed
Metadata
Title
Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates
Authors
J. Ward
C. Wood
K. Rouch
D. Pienkowski
H. H. Malluche
Publication date
01-09-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 9/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3661-0

Other articles of this Issue 9/2016

Osteoporosis International 9/2016 Go to the issue

Original Article

Patient-specific finite element estimated femur strength as a predictor of the risk of hip fracture: the effect of methodological determinants

Original Article

The effect of prolonged breast-feeding on the development of postmenopausal osteoporosis in population with insufficient calcium intake and vitamin D level

Original Article

Body mass index, risk of allogeneic red blood cell transfusion, and mortality in elderly patients undergoing hip fracture surgery

Original Article

Neuropeptide Y mediates glucocorticoid-induced osteoporosis and marrow adiposity in mice

Letter

An evidence-based perspective on warfarin and the growing skeleton

Review

The effects of weight loss approaches on bone mineral density in adults: a systematic review and meta-analysis of randomized controlled trials